Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 16/20 | 1.00 |
| ▸ | SPIN1 | Q9Y657 | 10/20 | 0.77 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028345 | 0.87 | EHMT2 (1.00) | EHMT2SPIN1EHMT1 | |
| SCHEMBL17106564 | 0.87 | EHMT2 (1.00) | EHMT2SPIN1EHMT1 | |
| SCHEMBL20028333 | 0.87 | EHMT2 (1.00) | EHMT2SPIN1EHMT1 | |
| SCHEMBL30051800 | 0.87 | EHMT2 (1.00) | EHMT2SPIN1EHMT1 | |
| SCHEMBL20028335 | 0.86 | EHMT2 (0.98) | EHMT2SPIN1EHMT1 | |
| SCHEMBL20028667 | 0.86 | EHMT2 (0.98) | EHMT2SPIN1EHMT1 | |
| SCHEMBL20028318 | 0.85 | EHMT2 (0.81) | EHMT2SPIN1EHMT1 | |
| SCHEMBL20028041 | 0.84 | EHMT2 (0.96) | EHMT2SPIN1EHMT1 | |
| SCHEMBL20028317 | 0.83 | EHMT2 (0.85) | EHMT2SPIN1EHMT1 | |
| SCHEMBL21667947 | 0.82 | EHMT2 (0.69) | EHMT2SPIN1EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284272-B2 | Inhibitors of histone methyltransferase G9a | ABBVIE INC. (US) | 2016-03-15 | — | — | US | claimed |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | ABBVIE INC. | 2015-10-01 | — | — | US | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4105203-A1 | SPIRO-CONDENSED INDOLE COMPOUNDS AS EHMT2 INHIBITORS | Epizyme Inc (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| WO-2018064557-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9284272-B2 | Inhibitors of histone methyltransferase G9a | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284272-B2 | Inhibitors of histone methyltransferase G9a | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | ABBVIE INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | ABBVIE INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | ABBVIE INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | EHMT2 1/4885SPIN1 3937/4885EHMT1 6/4885 |
| US-20200039961-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | SHMT1, BHMT, EHMT2 | EHMT2 3/4885SPIN1 1040/4885EHMT1 4/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | EHMT2 1/4885SPIN1 3937/4885EHMT1 6/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | EHMT2 1/4885SPIN1 3516/4885EHMT1 2/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | EHMT2 1/4885SPIN1 3937/4885EHMT1 6/4885 |
| US-20150274660-A1 | INHIBITORS OF HISTONE METHYLTRANSFERASE G9a | EHMT1, EHMT2, EZH2 | EHMT2 2/4885SPIN1 1994/4885EHMT1 1/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | EHMT2 1/4885SPIN1 3829/4885EHMT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.